Hyaluronic Acid-Based Nanogels Produced by Microfluidics-Facilitated Self-Assembly Improves the Safety Profile of the Cationic Host Defense Peptide Novicidin
- 775 Downloads
Cationic host defence peptides constitute a promising class of therapeutic drug leads with a wide range of therapeutic applications, including anticancer therapy, immunomodulation, and antimicrobial activity. Although potent and efficacious, systemic toxicity and low chemical stability have hampered their commercial development. To overcome these challenges a novel nanogel-based drug delivery system was designed.
The peptide novicidin was self-assembled with an octenyl succinic anhydride-modified analogue of hyaluronic acid, and this formulation was optimized using a microfluidics-based quality-by-design approach.
By applying design-of-experiment it was demonstrated that the encapsulation efficiency of novicidin (15% to 71%) and the zeta potential (−24 to −57 mV) of the nanogels could be tailored by changing the preparation process parameters, with a maximum peptide loading of 36 ± 4%. The nanogels exhibited good colloidal stability under different ionic strength conditions and allowed complete release of the peptide over 14 days. Furthermore, self-assembly of novicidin with hyaluronic acid into nanogels significantly improved the safety profile at least five-fold and six-fold when tested in HUVECs and NIH 3T3 cells, respectively, whilst showing no loss of antimicrobial activity against Escherichia coli and Staphylococcus aureus.
Formulation in nanogels could be a viable approach to improve the safety profile of host defence peptides.
KEY WORDSantimicrobial peptides hyaluronic acid hydrogel nanoparticles microfluidics nanogels
Dynamic light scattering
Dulbecco’s modified Eagle’s medium
Design of experiment
Fetal bovine serum
Hank’s balanced salt solution
Host defense peptides
Human umbilical vein endothelial cell
Minimum inhibitory concentration
Multiple linear regression
Nanoparticle tracking analysis
Octenyl succinic anhydride-modified hyaluronic acid
Transmission electron microscopy
ACKNOWLEDGMENTS AND DISCLOSURES
The authors acknowledge Prof. Robert Langer at MIT for his generous support and discussion on the use of microfluidic devices. We also acknowledge Karina Juul Vissing, Thara Qais Hussein and Maria Læssøe Pedersen for their technical support. Pall Thor Ingvarsson, PhD, is acknowledged for assistance with the experimental design; The Danish Agency for Science and Technology and Innovation (DanCARD, grant no. 06-097075) for financial support, The Core Facility for Integrated Microscopy, Faculty of Health and Medical Sciences, University of Copenhagen for providing access to imaging facilities and Adam Bohr, PhD, for his assistance. Lastly, Innovation Fund Denmark (041-2010-3) is acknowledged for co-financing the HPLC system.
- 9.Giuliani A, Pirri G, Nicoletto SF. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent Eur J Biol. 2007;2:1–33.Google Scholar
- 23.Gottlieb CT, Thomsen LE, Ingmer H, Mygind PH, Kristensen H-H, Gram L. Antimicrobial peptides effectively kill a broad spectrum of Listeria monocytogenes and Staphylococcus aureus strains independently of origin, sub-type, or virulence factor expression. BMC Microbiol. 2008;8:205.PubMedCentralPubMedCrossRefGoogle Scholar
- 30.CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically ; approved standard—ninth edition. CLSI document M07-A9. Wayne: Clinical and Laboratory Standards Institute; 2012.Google Scholar
- 38.Tossi A, Sandri L, Giangaspero A. Amphipathic, α-helical antimicrobial peptides. Biopolymers. 2000;55:4–30.Google Scholar